MedTrace Logo

Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine

NCT00853749 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2021-11-11

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to evaluate the immune response to 13-valent pneumococcal conjugate vaccine (13vPnCV) in children who as infants received either a complete series of PnCV versus a combination of PnCV and pneumococcal polysaccharide vaccine (PSV). This study is also intended to evaluate the safety of the 13vPnC.

Conditions

  • Invasive Pneumococcal Disease

Interventions

BIOLOGICAL

13-valent pneumococcal conjugate vaccine (13vPnC)

0.5 mL intramuscular injection

PROCEDURE

Blood draw

Collection of 10 mL of blood

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE

Eligibility

Min Age
5 Years
Max Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-05
Primary Completion
2009-12-16
Completion
2009-12-16

Countries

  • Iceland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00853749 on ClinicalTrials.gov